|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
ELV053262891 |
| 003 |
DE-627 |
| 005 |
20230624193341.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
210910s2021 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.pcd.2020.08.017
|2 doi
|
| 028 |
5 |
2 |
|a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001496.pica
|
| 035 |
|
|
|a (DE-627)ELV053262891
|
| 035 |
|
|
|a (ELSEVIER)S1751-9918(20)30253-9
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 082 |
0 |
4 |
|a 630
|q VZ
|
| 082 |
0 |
4 |
|a 640
|q VZ
|
| 082 |
0 |
4 |
|a 590
|q VZ
|
| 082 |
0 |
4 |
|a 610
|q VZ
|
| 082 |
0 |
4 |
|a 600
|q VZ
|
| 084 |
|
|
|a 50.70
|2 bkl
|
| 100 |
1 |
|
|a Wei, Xu-Bin
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: A network meta-analysis of large randomized trials
|
| 264 |
|
1 |
|c 2021
|
| 300 |
|
|
|a 4
|
| 336 |
|
|
|a nicht spezifiziert
|b zzz
|2 rdacontent
|
| 337 |
|
|
|a nicht spezifiziert
|b z
|2 rdamedia
|
| 338 |
|
|
|a nicht spezifiziert
|b zu
|2 rdacarrier
|
| 520 |
|
|
|a • The relative benefit of new antidiabetic drugs for cardiorenal endpoints is unclear. • The most efficacious drugs vary with different cardiorenal endpoints. • Subcutaneous semaglutide and albiglutide are most effective for cardiac events. • Canagliflozin and empagliflozin are most effective for heart failure hospitalization. • Dapagliflozin and empagliflozin are most effective for kidney function progression.
|
| 650 |
|
7 |
|a CVD
|2 Elsevier
|
| 650 |
|
7 |
|a GLP-1 RAs
|2 Elsevier
|
| 650 |
|
7 |
|a ACD
|2 Elsevier
|
| 650 |
|
7 |
|a RCT
|2 Elsevier
|
| 650 |
|
7 |
|a KFP
|2 Elsevier
|
| 650 |
|
7 |
|a MACE
|2 Elsevier
|
| 650 |
|
7 |
|a CI
|2 Elsevier
|
| 650 |
|
7 |
|a HHF
|2 Elsevier
|
| 650 |
|
7 |
|a SUCRA
|2 Elsevier
|
| 650 |
|
7 |
|a HR
|2 Elsevier
|
| 650 |
|
7 |
|a MI
|2 Elsevier
|
| 650 |
|
7 |
|a SGLT2 inhibitors
|2 Elsevier
|
| 700 |
1 |
|
|a Wei, Wei
|4 oth
|
| 700 |
1 |
|
|a Ding, Liang-Liang
|4 oth
|
| 700 |
1 |
|
|a Liu, Shu-Yan
|4 oth
|
| 773 |
0 |
8 |
|i Enthalten in
|n Elsevier
|a David, Lauren A. ELSEVIER
|t A pilot randomized controlled trial examining the feasibility, acceptability, and efficacy of Adapted Motivational Interviewing for post-operative bariatric surgery patients
|d 2016
|g Amsterdam [u.a.]
|w (DE-627)ELV024210129
|
| 773 |
1 |
8 |
|g volume:15
|g year:2021
|g number:2
|g pages:208-211
|g extent:4
|
| 856 |
4 |
0 |
|u https://doi.org/10.1016/j.pcd.2020.08.017
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_U
|
| 912 |
|
|
|a GBV_ELV
|
| 912 |
|
|
|a SYSFLAG_U
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_227
|
| 912 |
|
|
|a GBV_ILN_350
|
| 936 |
b |
k |
|a 50.70
|j Energie: Allgemeines
|q VZ
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 15
|j 2021
|e 2
|h 208-211
|g 4
|